Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics Inc. (NASDAQ: CYCN) is a Cambridge, Massachusetts-based biopharmaceutical company incorporated in 2018. The company focuses on developing treatments for serious diseases using novel soluble guanylate cyclase (sGC) stimulators, with programs spanning both the central nervous system and the peripheral system. Its pipeline includes Olinciguat, an oral vascular sGC stimulator currently in Phase 2 testing for cardiovascular diseases, and Praliciguat, a systemic sGC stimulator being developed for rare kidney disease. Cyclerion also has a license agreement with Akebia covering the development, manufacture, medical affairs, and commercialization of Praliciguat and related products.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CYCN
|
$4.16
|
-2.2% Downside
|
Fair
|
$8
|
88.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
3.8x
|
10.3x
|
19.581 M
|
12.84 M
|
0.0%
|
25.5%
|
-52.4
|
67.3%
|
